Vascular Access Device Market by Type (Central Venous Catheters, Peripheral Vascular Access Devices), Age Group (Adult, Geriatric, Pediatric), End User, Application - Global Forecast 2025-2032
Description
The Vascular Access Device Market was valued at USD 8.64 billion in 2024 and is projected to grow to USD 9.15 billion in 2025, with a CAGR of 6.05%, reaching USD 13.84 billion by 2032.
Framing the strategic context for vascular access devices with a clear statement of scope objectives and the primary clinical and commercial challenges that drive decision-making
The vascular access device landscape is at a strategic inflection point driven by shifting clinical needs, patient demographics, and technological advances. This executive-level introduction clarifies the scope of analysis, articulates the primary research objectives, and identifies the critical challenges that stakeholders must confront when making investment, procurement, and clinical adoption decisions. By establishing common terminology and a clear problem statement, the introduction primes decision-makers to evaluate device categories, clinical pathways, and end-user workflows with greater clarity and purpose.
Framing begins with an examination of clinical imperatives that elevate the importance of reliable vascular access, including the increasing volume of outpatient infusions, the growing demand for safer long-term venous access, and the intensifying focus on infection prevention. Contextualizing these trends with operational pressures faced by hospitals, home care providers, and surgical centers surfaces the central trade-offs between device performance, ease of use, and total cost of care. This baseline allows readers to understand subsequent analysis in light of real-world constraints and stakeholder incentives.
Finally, the introduction sets expectations for actionable outcomes: rigorous assessment of technology trajectories, identification of high-impact clinical and commercial levers, and recommendations that balance near-term operational gains with longer-term strategic positioning. It thereby creates a roadmap for the remainder of the report and equips readers to translate insight into prioritized action.
How material innovation regulatory tightening and the shift to outpatient and home-based care are reshaping clinical practice procurement priorities and competitive differentiation
The vascular access device market is experiencing transformative shifts that are redefining clinical practice, procurement strategies, and innovation priorities. Advances in catheter materials and coating technologies are reducing complication rates and extending indwelling durations, which in turn change clinician preferences and procurement criteria. Concurrently, minimally invasive insertion techniques and data-enabled devices are enabling safer bedside procedures and more robust post-procedural monitoring, shifting the competitive landscape toward integrated solutions rather than single-function disposables.
At the same time, healthcare delivery is migrating toward outpatient and home-based care settings, which places a premium on devices that are user-friendly for non-specialist caregivers and that simplify maintenance protocols. This shift is amplified by demographic changes, including aging populations and a rise in chronic disease management outside traditional hospital environments. Regulators and payers are reacting by tightening standards for device safety while also encouraging products that demonstrably reduce avoidable complications and readmissions, creating opportunities for vendors who can provide strong clinical evidence and real-world performance data.
Taken together, these shifts mean that successful market participants must integrate device innovation with clinical evidence-generation, user training programs, and service-oriented commercial models. Companies that align product development with end-user workflow optimization and that provide measurable improvements in patient outcomes will be best positioned to capture elevated levels of clinical trust and procurement preference.
Supply chain reshaping and procurement recalibration driven by the cumulative tariffs introduced in 2025 and the resultant shift toward regionalized manufacturing and total cost analysis
The cumulative impact of U.S. tariff changes implemented in 2025 has introduced a new layer of complexity to supply chain and procurement decisions for vascular access devices. Manufacturers that rely on globalized component sourcing have had to reassess supplier mixes and production footprints to mitigate increased landed costs. For many organizations this has accelerated a strategic rebalancing from purely cost-driven sourcing to a hybrid approach that weighs tariff exposure, supplier reliability, and regulatory compliance risk.
In response, several OEMs and contract manufacturers initiated regionalization strategies to reduce exposure to tariff volatility, prioritizing suppliers in tariff-favored jurisdictions and increasing utilization of domestic manufacturing capacity where feasible. This shift, while mitigating some pricing pressures, has required capital investment and retooling cycles that influence lead times and product availability. For procurement teams, the immediate consequence has been a renewed emphasis on total cost of ownership analysis that explicitly incorporates tariff scenarios, longer-term supply agreements, and inventory buffers designed to protect clinical operations from disruption.
Beyond cost impacts, tariff-driven supply adjustments have also influenced product innovation timelines. Companies facing higher import costs have delayed lower-margin product launches and redirected R&D budgets toward feature-differentiated portfolios with clearer clinical value propositions. Consequently, the market has seen a concentration of investment in devices that offer measurable reductions in complications and that fit within value-based contracting frameworks, altering the competitive calculus across the landscape.
Segment-level dynamics and cross-cutting clinical use cases that reveal where device design end-user workflows and age-specific needs create differentiated commercial opportunities
A clear understanding of segmentation dynamics is essential to interpret where clinical demand and commercial opportunity converge within the vascular access device ecosystem. When examined by device type, the market diverges between central venous catheters and peripheral vascular access devices, with the latter further differentiated into long peripheral intravenous catheters and short peripheral intravenous catheters; these distinctions influence clinician selection criteria, insertion technique preferences, and training needs. Age-based segmentation highlights differing clinical imperatives across adult, geriatric, and pediatric populations where vascular anatomy, access durability needs, and complication risk profiles necessitate tailored device design and usage protocols.
End-user segmentation illuminates operational and economic drivers, as ambulatory surgical centers, home healthcare settings, and hospitals and clinics each impose unique constraints on device selection. Ambulatory surgical centers prioritize rapid insertion and turnover, home healthcare requires simplified maintenance and patient education, and hospitals demand robust infection control features and compatibility with complex clinical workflows. Application-based segmentation-covering blood transfusion, diagnostics and testing, and drug administration-further refines product requirements; within drug administration, specific use cases such as antibiotic infusion and chemotherapy create high-stakes contexts where device reliability and safety are non-negotiable.
Intersections among these segmentation axes reveal where incremental innovation delivers outsized returns. For example, pediatric-friendly peripheral devices designed for chemotherapy administration in home settings address an acute clinical need that blends device ergonomics with caregiver-focused usability. By analyzing demand through the prisms of type, age group, end user, and application, stakeholders can prioritize investments that maximize clinical impact and align with procurement decision-making.
Regional go-to-market imperatives and evidence-driven commercialization strategies tailored to the Americas Europe Middle East & Africa and Asia-Pacific realities and procurement behaviors
Geographic trends shape manufacturing priorities, regulatory strategies, and go-to-market approaches across the vascular access device sector. In the Americas, robust hospital networks, high outpatient infusion volumes, and established reimbursement mechanisms drive demand for devices that demonstrate reductions in complications and streamline care transitions. Clinical research activity and large-scale health systems in this region also create pathways for rapid evidence generation and pilot deployments, making it an attractive proving ground for new device introductions.
Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and varying levels of healthcare infrastructure create a complex landscape for market entry. Procurement cycles may be longer and influenced by national tendering processes, which elevates the importance of health economic data and localized clinical partnerships. Meanwhile, Asia-Pacific presents a mix of rapidly modernizing healthcare systems, constrained public budgets in some countries, and large private sector players in others; this diversity rewards adaptable commercial models, including licensing, local manufacturing partnerships, and targeted product configurations that meet regional clinical and cost requirements.
Taken together, these regional patterns imply that one-size-fits-all strategies are unlikely to succeed. Instead, manufacturers should design regionalized market entry plans that combine evidence generation, regulatory navigation, and supply chain optimization to meet the unique needs and purchasing behaviors of each geography.
How innovation evidence and service-enabled commercial models are redefining competitive advantage and supplier selection in the vascular access device landscape
Competitive dynamics in the vascular access device arena are increasingly defined by the convergence of product innovation, clinical evidence, and service-oriented commercial models. Market-leading firms are investing in integrated solutions that pair device hardware with procedural training, electronic tracking, and post-market surveillance systems to differentiate on both clinical outcomes and operational value. This integration reflects a broader trend toward outcome-based selling, in which manufacturers must demonstrate reductions in infection rates, catheter-related complications, and overall care burden to secure preferred status with health systems.
Partnerships and strategic alliances are another defining characteristic of the competitive landscape. Collaborations between device manufacturers and technology providers focused on sensors, data analytics, and remote monitoring are expanding the functional envelope of vascular access solutions. These alliances enable richer real-world evidence generation and support value-based contracting conversations with large purchasers. At the same time, contract manufacturing and localized production agreements are becoming more common as firms seek to reduce tariff exposure and improve supply resilience.
Given these dynamics, companies that combine differentiated clinical performance with demonstrable operational benefits and flexible commercial models will command stronger negotiating positions. Investing in robust post-market data collection, clinician education programs, and scalable service frameworks will be decisive for firms seeking to scale adoption across diverse care settings.
Practical strategic moves for manufacturers and suppliers to accelerate clinical adoption manage supply risk and establish defensible commercial differentiation in the short and medium term
Industry leaders should adopt a set of pragmatic, action-oriented moves to convert insight into measurable progress. First, prioritize product developments that address demonstrable clinical pain points, such as minimizing catheter-related infections and simplifying maintenance for non-specialist caregivers; aligning R&D with validated clinician needs reduces adoption friction and strengthens negotiating leverage with large purchasers. Second, invest in integrated evidence-generation programs that pair randomized controlled trials with pragmatic real-world studies and registry data to build a compelling value narrative for payers and providers.
Next, restructure commercial models to offer bundled solutions that combine devices, training, and post-market monitoring services. Such bundles align provider incentives around outcomes and create stickier customer relationships. In parallel, hedge supply-chain risk by diversifying supplier bases, exploring regional manufacturing partnerships, and renegotiating long-term supply agreements that include price-stability clauses to manage tariff volatility. Finally, accelerate internal capabilities in health economics and reimbursement strategy to translate clinical benefits into compelling cost-effectiveness arguments that resonate with procurement teams and payers.
Taken together, these recommendations position industry leaders to deliver clinically meaningful innovations while managing operational risk and creating defensible commercial differentiation. Executing on this set of actions requires coordinated investment across product, clinical affairs, supply chain, and commercial functions to translate strategic intent into market outcomes.
Integrated methodological approach combining primary qualitative interviews secondary evidence synthesis and scenario analysis to ensure robust actionable insights and validated conclusions
The research methodology underpinning this report integrates primary qualitative engagement, secondary source synthesis, and rigorous triangulation to ensure validity and relevance. Primary research involved structured interviews with clinicians, procurement leaders, and supply chain managers across acute care hospitals, ambulatory surgical centers, and home health organizations, designed to capture real-world adoption drivers, pain points, and operational constraints. Interviews were supplemented by discussions with device developers, contract manufacturers, and regulatory experts to surface technology trends and commercialization strategies.
Secondary research drew on peer-reviewed clinical literature, regulatory filings, and public datasets to map safety profiles, procedural best practices, and documented outcomes for key device categories. Where appropriate, findings from diverse sources were cross-validated to mitigate bias and to ensure that conclusions reflect consistent patterns rather than isolated observations. The analysis also incorporated scenario-based assessments to evaluate the implications of regulatory shifts, supply-chain disruptions, and changes in care delivery models.
Finally, insights were synthesized using a structured framework that links clinical needs to device capabilities, procurement behaviors, and regional market dynamics. This approach supports clear line-of-sight from evidence to recommendation and enables stakeholders to apply findings directly to product development, clinical validation, and commercial strategy.
Synthesis of strategic imperatives and operational levers that enable stakeholders to prioritize investments reduce complications and secure sustainable competitive advantage in vascular access
In conclusion, the vascular access device sector is being reshaped by material innovation, changing care settings, regulatory expectations, and supply-chain realignment. These forces create opportunities for companies that can demonstrate superior clinical performance, offer integrated service-oriented commercial models, and adapt manufacturing footprints to mitigate trade-related risks. Decision-makers must therefore prioritize investments that produce measurable reductions in complications and that simplify workflows for a variety of care settings, from acute hospitals to home-based infusion programs.
Strategic success will come from aligning product development with rigorous evidence-generation, forging partnerships that enhance product functionality with digital and monitoring capabilities, and constructing resilient supply networks that reduce exposure to tariff and trade volatility. By focusing on these key areas, stakeholders can drive safer patient care, reduce avoidable costs, and capture sustainable competitive advantage. The convergence of clinical need and technological possibility makes this an opportune moment to act decisively and to convert insight into tangible improvements in patient outcomes and operational performance.
Please Note: PDF & Excel + Online Access - 1 Year
Framing the strategic context for vascular access devices with a clear statement of scope objectives and the primary clinical and commercial challenges that drive decision-making
The vascular access device landscape is at a strategic inflection point driven by shifting clinical needs, patient demographics, and technological advances. This executive-level introduction clarifies the scope of analysis, articulates the primary research objectives, and identifies the critical challenges that stakeholders must confront when making investment, procurement, and clinical adoption decisions. By establishing common terminology and a clear problem statement, the introduction primes decision-makers to evaluate device categories, clinical pathways, and end-user workflows with greater clarity and purpose.
Framing begins with an examination of clinical imperatives that elevate the importance of reliable vascular access, including the increasing volume of outpatient infusions, the growing demand for safer long-term venous access, and the intensifying focus on infection prevention. Contextualizing these trends with operational pressures faced by hospitals, home care providers, and surgical centers surfaces the central trade-offs between device performance, ease of use, and total cost of care. This baseline allows readers to understand subsequent analysis in light of real-world constraints and stakeholder incentives.
Finally, the introduction sets expectations for actionable outcomes: rigorous assessment of technology trajectories, identification of high-impact clinical and commercial levers, and recommendations that balance near-term operational gains with longer-term strategic positioning. It thereby creates a roadmap for the remainder of the report and equips readers to translate insight into prioritized action.
How material innovation regulatory tightening and the shift to outpatient and home-based care are reshaping clinical practice procurement priorities and competitive differentiation
The vascular access device market is experiencing transformative shifts that are redefining clinical practice, procurement strategies, and innovation priorities. Advances in catheter materials and coating technologies are reducing complication rates and extending indwelling durations, which in turn change clinician preferences and procurement criteria. Concurrently, minimally invasive insertion techniques and data-enabled devices are enabling safer bedside procedures and more robust post-procedural monitoring, shifting the competitive landscape toward integrated solutions rather than single-function disposables.
At the same time, healthcare delivery is migrating toward outpatient and home-based care settings, which places a premium on devices that are user-friendly for non-specialist caregivers and that simplify maintenance protocols. This shift is amplified by demographic changes, including aging populations and a rise in chronic disease management outside traditional hospital environments. Regulators and payers are reacting by tightening standards for device safety while also encouraging products that demonstrably reduce avoidable complications and readmissions, creating opportunities for vendors who can provide strong clinical evidence and real-world performance data.
Taken together, these shifts mean that successful market participants must integrate device innovation with clinical evidence-generation, user training programs, and service-oriented commercial models. Companies that align product development with end-user workflow optimization and that provide measurable improvements in patient outcomes will be best positioned to capture elevated levels of clinical trust and procurement preference.
Supply chain reshaping and procurement recalibration driven by the cumulative tariffs introduced in 2025 and the resultant shift toward regionalized manufacturing and total cost analysis
The cumulative impact of U.S. tariff changes implemented in 2025 has introduced a new layer of complexity to supply chain and procurement decisions for vascular access devices. Manufacturers that rely on globalized component sourcing have had to reassess supplier mixes and production footprints to mitigate increased landed costs. For many organizations this has accelerated a strategic rebalancing from purely cost-driven sourcing to a hybrid approach that weighs tariff exposure, supplier reliability, and regulatory compliance risk.
In response, several OEMs and contract manufacturers initiated regionalization strategies to reduce exposure to tariff volatility, prioritizing suppliers in tariff-favored jurisdictions and increasing utilization of domestic manufacturing capacity where feasible. This shift, while mitigating some pricing pressures, has required capital investment and retooling cycles that influence lead times and product availability. For procurement teams, the immediate consequence has been a renewed emphasis on total cost of ownership analysis that explicitly incorporates tariff scenarios, longer-term supply agreements, and inventory buffers designed to protect clinical operations from disruption.
Beyond cost impacts, tariff-driven supply adjustments have also influenced product innovation timelines. Companies facing higher import costs have delayed lower-margin product launches and redirected R&D budgets toward feature-differentiated portfolios with clearer clinical value propositions. Consequently, the market has seen a concentration of investment in devices that offer measurable reductions in complications and that fit within value-based contracting frameworks, altering the competitive calculus across the landscape.
Segment-level dynamics and cross-cutting clinical use cases that reveal where device design end-user workflows and age-specific needs create differentiated commercial opportunities
A clear understanding of segmentation dynamics is essential to interpret where clinical demand and commercial opportunity converge within the vascular access device ecosystem. When examined by device type, the market diverges between central venous catheters and peripheral vascular access devices, with the latter further differentiated into long peripheral intravenous catheters and short peripheral intravenous catheters; these distinctions influence clinician selection criteria, insertion technique preferences, and training needs. Age-based segmentation highlights differing clinical imperatives across adult, geriatric, and pediatric populations where vascular anatomy, access durability needs, and complication risk profiles necessitate tailored device design and usage protocols.
End-user segmentation illuminates operational and economic drivers, as ambulatory surgical centers, home healthcare settings, and hospitals and clinics each impose unique constraints on device selection. Ambulatory surgical centers prioritize rapid insertion and turnover, home healthcare requires simplified maintenance and patient education, and hospitals demand robust infection control features and compatibility with complex clinical workflows. Application-based segmentation-covering blood transfusion, diagnostics and testing, and drug administration-further refines product requirements; within drug administration, specific use cases such as antibiotic infusion and chemotherapy create high-stakes contexts where device reliability and safety are non-negotiable.
Intersections among these segmentation axes reveal where incremental innovation delivers outsized returns. For example, pediatric-friendly peripheral devices designed for chemotherapy administration in home settings address an acute clinical need that blends device ergonomics with caregiver-focused usability. By analyzing demand through the prisms of type, age group, end user, and application, stakeholders can prioritize investments that maximize clinical impact and align with procurement decision-making.
Regional go-to-market imperatives and evidence-driven commercialization strategies tailored to the Americas Europe Middle East & Africa and Asia-Pacific realities and procurement behaviors
Geographic trends shape manufacturing priorities, regulatory strategies, and go-to-market approaches across the vascular access device sector. In the Americas, robust hospital networks, high outpatient infusion volumes, and established reimbursement mechanisms drive demand for devices that demonstrate reductions in complications and streamline care transitions. Clinical research activity and large-scale health systems in this region also create pathways for rapid evidence generation and pilot deployments, making it an attractive proving ground for new device introductions.
Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and varying levels of healthcare infrastructure create a complex landscape for market entry. Procurement cycles may be longer and influenced by national tendering processes, which elevates the importance of health economic data and localized clinical partnerships. Meanwhile, Asia-Pacific presents a mix of rapidly modernizing healthcare systems, constrained public budgets in some countries, and large private sector players in others; this diversity rewards adaptable commercial models, including licensing, local manufacturing partnerships, and targeted product configurations that meet regional clinical and cost requirements.
Taken together, these regional patterns imply that one-size-fits-all strategies are unlikely to succeed. Instead, manufacturers should design regionalized market entry plans that combine evidence generation, regulatory navigation, and supply chain optimization to meet the unique needs and purchasing behaviors of each geography.
How innovation evidence and service-enabled commercial models are redefining competitive advantage and supplier selection in the vascular access device landscape
Competitive dynamics in the vascular access device arena are increasingly defined by the convergence of product innovation, clinical evidence, and service-oriented commercial models. Market-leading firms are investing in integrated solutions that pair device hardware with procedural training, electronic tracking, and post-market surveillance systems to differentiate on both clinical outcomes and operational value. This integration reflects a broader trend toward outcome-based selling, in which manufacturers must demonstrate reductions in infection rates, catheter-related complications, and overall care burden to secure preferred status with health systems.
Partnerships and strategic alliances are another defining characteristic of the competitive landscape. Collaborations between device manufacturers and technology providers focused on sensors, data analytics, and remote monitoring are expanding the functional envelope of vascular access solutions. These alliances enable richer real-world evidence generation and support value-based contracting conversations with large purchasers. At the same time, contract manufacturing and localized production agreements are becoming more common as firms seek to reduce tariff exposure and improve supply resilience.
Given these dynamics, companies that combine differentiated clinical performance with demonstrable operational benefits and flexible commercial models will command stronger negotiating positions. Investing in robust post-market data collection, clinician education programs, and scalable service frameworks will be decisive for firms seeking to scale adoption across diverse care settings.
Practical strategic moves for manufacturers and suppliers to accelerate clinical adoption manage supply risk and establish defensible commercial differentiation in the short and medium term
Industry leaders should adopt a set of pragmatic, action-oriented moves to convert insight into measurable progress. First, prioritize product developments that address demonstrable clinical pain points, such as minimizing catheter-related infections and simplifying maintenance for non-specialist caregivers; aligning R&D with validated clinician needs reduces adoption friction and strengthens negotiating leverage with large purchasers. Second, invest in integrated evidence-generation programs that pair randomized controlled trials with pragmatic real-world studies and registry data to build a compelling value narrative for payers and providers.
Next, restructure commercial models to offer bundled solutions that combine devices, training, and post-market monitoring services. Such bundles align provider incentives around outcomes and create stickier customer relationships. In parallel, hedge supply-chain risk by diversifying supplier bases, exploring regional manufacturing partnerships, and renegotiating long-term supply agreements that include price-stability clauses to manage tariff volatility. Finally, accelerate internal capabilities in health economics and reimbursement strategy to translate clinical benefits into compelling cost-effectiveness arguments that resonate with procurement teams and payers.
Taken together, these recommendations position industry leaders to deliver clinically meaningful innovations while managing operational risk and creating defensible commercial differentiation. Executing on this set of actions requires coordinated investment across product, clinical affairs, supply chain, and commercial functions to translate strategic intent into market outcomes.
Integrated methodological approach combining primary qualitative interviews secondary evidence synthesis and scenario analysis to ensure robust actionable insights and validated conclusions
The research methodology underpinning this report integrates primary qualitative engagement, secondary source synthesis, and rigorous triangulation to ensure validity and relevance. Primary research involved structured interviews with clinicians, procurement leaders, and supply chain managers across acute care hospitals, ambulatory surgical centers, and home health organizations, designed to capture real-world adoption drivers, pain points, and operational constraints. Interviews were supplemented by discussions with device developers, contract manufacturers, and regulatory experts to surface technology trends and commercialization strategies.
Secondary research drew on peer-reviewed clinical literature, regulatory filings, and public datasets to map safety profiles, procedural best practices, and documented outcomes for key device categories. Where appropriate, findings from diverse sources were cross-validated to mitigate bias and to ensure that conclusions reflect consistent patterns rather than isolated observations. The analysis also incorporated scenario-based assessments to evaluate the implications of regulatory shifts, supply-chain disruptions, and changes in care delivery models.
Finally, insights were synthesized using a structured framework that links clinical needs to device capabilities, procurement behaviors, and regional market dynamics. This approach supports clear line-of-sight from evidence to recommendation and enables stakeholders to apply findings directly to product development, clinical validation, and commercial strategy.
Synthesis of strategic imperatives and operational levers that enable stakeholders to prioritize investments reduce complications and secure sustainable competitive advantage in vascular access
In conclusion, the vascular access device sector is being reshaped by material innovation, changing care settings, regulatory expectations, and supply-chain realignment. These forces create opportunities for companies that can demonstrate superior clinical performance, offer integrated service-oriented commercial models, and adapt manufacturing footprints to mitigate trade-related risks. Decision-makers must therefore prioritize investments that produce measurable reductions in complications and that simplify workflows for a variety of care settings, from acute hospitals to home-based infusion programs.
Strategic success will come from aligning product development with rigorous evidence-generation, forging partnerships that enhance product functionality with digital and monitoring capabilities, and constructing resilient supply networks that reduce exposure to tariff and trade volatility. By focusing on these key areas, stakeholders can drive safer patient care, reduce avoidable costs, and capture sustainable competitive advantage. The convergence of clinical need and technological possibility makes this an opportune moment to act decisively and to convert insight into tangible improvements in patient outcomes and operational performance.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of antimicrobial-impregnated central venous catheters to reduce bloodstream infections
- 5.2. Integration of IoT-enabled pressure sensors in vascular access ports for continuous flow monitoring and data analytics
- 5.3. Growing demand for ultrasound-guided peripheral intravenous catheters in outpatient oncology and infusion clinics
- 5.4. Emergence of closed system transfer devices for needleless drug administration to improve safety and compliance
- 5.5. Widening use of midline catheters in home healthcare for prolonged antibiotic and nutrition infusion therapies
- 5.6. Development of bioresorbable polymeric vascular grafts to address small vessel disease in diabetic patient populations
- 5.7. Surge in robotic-assisted insertion systems for central venous access to enhance precision and reduce procedural complications
- 5.8. Increasing regulatory approvals for needle-free connectors with antimicrobial barrier technology to curb contamination risks
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Vascular Access Device Market, by Type
- 8.1. Central Venous Catheters
- 8.2. Peripheral Vascular Access Devices
- 8.2.1. Long Peripheral Intravenous Catheter
- 8.2.2. Short Peripheral Intravenous Catheter
- 9. Vascular Access Device Market, by Age Group
- 9.1. Adult
- 9.2. Geriatric
- 9.3. Pediatric
- 10. Vascular Access Device Market, by End User
- 10.1. Ambulatory Surgical Centers
- 10.2. Home Healthcare Settings
- 10.3. Hospitals & Clinics
- 11. Vascular Access Device Market, by Application
- 11.1. Blood Transfusion
- 11.2. Diagnostics & Testing
- 11.3. Drug Administration
- 11.3.1. Antibiotic Infusion
- 11.3.2. Chemotherapy
- 12. Vascular Access Device Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Vascular Access Device Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Vascular Access Device Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. 3M Company
- 15.3.2. Access Vascular, Inc.
- 15.3.3. AMECATH
- 15.3.4. AngioDynamics, Inc.
- 15.3.5. Argon Medical Devices, Inc.
- 15.3.6. Asahi Kasei Medical Co., Ltd.
- 15.3.7. B. Braun Melsungen AG
- 15.3.8. Baxter International Inc.
- 15.3.9. Becton, Dickinson and Company
- 15.3.10. Cook Medical, Inc.
- 15.3.11. Edwards Lifesciences Corporation
- 15.3.12. Fresenius Medical Care AG & Co. KGaA
- 15.3.13. Fujifilm Sonosite, Inc.
- 15.3.14. ICU Medical, Inc.
- 15.3.15. Kimal PLC
- 15.3.16. Medical Components, Inc.
- 15.3.17. Medtronic PLC
- 15.3.18. Nipro Medical Corporation
- 15.3.19. Prodimed
- 15.3.20. Siemens Healthcare AG
- 15.3.21. Teleflex Incorporated
- 15.3.22. Terumo Corporation
- 15.3.23. Versago Vascular Access
- 15.3.24. Vygon SA
- 15.3.25. W. L. Gore & Associates, Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
